Lytic Induction Therapy Against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Aug 5

PMID 32748879

Citations 22

Authors

Stephanie Pei Tung Yiu

Mike Dorothea

Kwai Fung Hui

Alan Kwok Shing Chiang

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV) lytic induction therapy is an emerging virus-targeted therapeutic approach that exploits the presence of EBV in tumor cells to confer specific killing effects against EBV-associated malignancies. Efforts have been made in the past years to uncover the mechanisms of EBV latent-lytic switch and discover different classes of chemical compounds that can reactivate the EBV lytic cycle. Despite the growing list of compounds showing potential to be used in the lytic induction therapy, only a few are being tested in clinical trials, with varying degrees of success. This review will summarize the current knowledge on EBV lytic reactivation, the major hurdles of translating the lytic induction therapy into clinical settings, and highlight some potential strategies in the future development of this therapy for EBV-related lymphoid and epithelial malignancies.

Citing Articles

The Histone Demethylase LSD1/ZNF217/CoREST Complex is a Major Restriction Factor of Epstein-Barr Virus Lytic Reactivation.

Liao Y, Gewurz B, Yan J, Kong I, Li Z, Ding W Res Sq. 2025; .

PMID: 39877093 PMC: 11774438. DOI: 10.21203/rs.3.rs-5649616/v1.

Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges.

Sugiokto F, Li R Viruses. 2025; 17(1).

PMID: 39861899 PMC: 11768851. DOI: 10.3390/v17010110.

Identifying the key regulators orchestrating Epstein-Barr virus reactivation.

Wang Y, Yu J, Pei Y Front Microbiol. 2024; 15:1505191.

PMID: 39703703 PMC: 11655498. DOI: 10.3389/fmicb.2024.1505191.

Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56 and NKG2AKIRCD56 subsets.

Desimio M, Covino D, Cancrini C, Doria M Front Immunol. 2024; 15:1467304.

PMID: 39676862 PMC: 11638013. DOI: 10.3389/fimmu.2024.1467304.

Research landmarks on the 60th anniversary of Epstein-Barr virus.

Zhong L, Xie C, Zhang L, Yang Y, Liu Y, Zhao G Sci China Life Sci. 2024; 68(2):354-380.

PMID: 39505801 DOI: 10.1007/s11427-024-2766-0.

References

Kim S, Kim J, Ki C, Ko Y, Kim J, Kim W . Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol. 2015; 27(3):508-13. DOI: 10.1093/annonc/mdv596. View

Han H, Jain A, Truica M, Izquierdo-Ferrer J, Anker J, Lysy B . Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019; 36(5):483-497.e15. PMC: 6939458. DOI: 10.1016/j.ccell.2019.10.001. View

Yiu S, Hui K, Munz C, Lo K, Tsao S, Kao R . Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma. Cancers (Basel). 2019; 11(12). PMC: 6966612. DOI: 10.3390/cancers11121871. View

Li H, Liu S, Hu J, Luo X, Li N, Bode A . Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci. 2016; 12(11):1309-1318. PMC: 5118777. DOI: 10.7150/ijbs.16564. View

Lee D, Sugden B . The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene. 2007; 27(20):2833-42. DOI: 10.1038/sj.onc.1210946. View

Gutsch D, Zhang Q, Stein B, Blanar M, Baldwin A, Kenney S . The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol. 1994; 14(3):1939-48. PMC: 358552. DOI: 10.1128/mcb.14.3.1939-1948.1994. View

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H . A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015; 59(4):2062-71. PMC: 4356785. DOI: 10.1128/AAC.04534-14. View

Giunco S, Celeghin A, Gianesin K, Dolcetti R, Indraccolo S, De Rossi A . Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death Dis. 2015; 6:e1774. PMC: 4669716. DOI: 10.1038/cddis.2015.145. View

Feng W, Kenney S . Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006; 66(17):8762-9. DOI: 10.1158/0008-5472.CAN-06-1006. View

10.

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

11.

Wu C, Liu M, Chang Y, Fang C, Chou S, Liao H . Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res. 2009; 38(6):1932-49. PMC: 2847232. DOI: 10.1093/nar/gkp1169. View

12.

Shirley C, Chen J, Shamay M, Li H, Zahnow C, Hayward S . Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood. 2011; 117(23):6297-303. PMC: 3122948. DOI: 10.1182/blood-2011-01-332379. View

13.

He S, Li Q, Jiang X, Lu X, Feng F, Qu W . Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy. J Med Chem. 2017; 61(11):4656-4687. DOI: 10.1021/acs.jmedchem.7b01019. View

14.

Yang J, Deng X, Deng L, Gu H, Fan W, Cao Y . Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res. 2004; 23(3):495-506. View

15.

Yao J, Duan L, Fan M, Wu X . Gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells. Oral Dis. 2007; 13(6):555-63. DOI: 10.1111/j.1601-0825.2006.01334.x. View

16.

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

17.

Hedvat M, Huszar D, Herrmann A, Gozgit J, Schroeder A, Sheehy A . The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16(6):487-97. PMC: 2812011. DOI: 10.1016/j.ccr.2009.10.015. View

18.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

19.

Luftig M, Yasui T, Soni V, Kang M, Jacobson N, Cahir-McFarland E . Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci U S A. 2003; 101(1):141-6. PMC: 314152. DOI: 10.1073/pnas.2237183100. View

20.

Greten F, Karin M . Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med. 2010; 16(10):1085-7. DOI: 10.1038/nm1010-1085. View